Table 1 Clinicopathological characteristics
TME (n = 25) | TTE (n = 35) | p value* | |
Median age (range) | 66 (43–78) | 66 (51–82) | 0.96 |
Sex (M/F) | 23/2 | 28/7 | 0.28 |
Median BMI (range) | 22.4 (17.9–28.6) | 22.2 (17.5–29.7) | 0.55 |
ECOG-PS (0/1) | 9/16 | 10/25 | 0.58 |
Brinkman Index (0/ 1–600/ 601–1200/ 1201-) | 7/10/5/3 | 7/12/13/3 | 0.55 |
Location (Proximal/Middle/Distal/EGJ) | 2/18/4/1 | 2/19/8/6 | 0.35 |
Anastomosis site (Cervical/Intrathoracic) | 25/0 | 7/28 | <.0001* |
Number of three-field lymphadenectomies (%) | 22 (88.0%) | 23 (65.7%) | 0.07 |
Clinical classification | |||
cT Status (0/1/2/3) | 0/17/8/0 | 2/13/10/10 | 0.0043* |
cN Status (0/1/2) | 20/5/0 | 28/6/1 | 1.00 |
Pathological classification | |||
pT Status (0/1/2/3) | 0/19/3/3 | 1/16/2/16 | 0.01* |
pN Status (0/1/2/3) | 13/6/5/1 | 16/12/5/2 | 0.16 |
pStage (0/IA/IB/IIA/IIB/IIIA/IIIB/IIIC) | 0/10/2/1/5/6/0/1 | 1/11/1/3/5/8/5/1 | 0.52 |
Resection status (R0/R1/R2) | 25/0/0 | 34/1/0 | 1.00 |
Histological type (SCC/AC/Other) | 24/0/1 | 31/3/1 | 0.38 |
Number of cases (%) | p value | ||
Neoadjuvant chemotherapy: n (%) | 2 (8.0%) | 11 (31.4%) | 0.054 |
Adjuvant chemotherapy: n (%) | 9 (36.0%) | 11 (31.4%) | 0.78 |